أفضل المعالجين في تركيا - توب -84 أطباء

يلبي المحتوى سياسة التحرير Bookimed ويتم مراجعتها طبياً من قبل
فهد مولود - طبيب عام. حاصل على 4 جوائز علمية. خدم في غرب آسيا. رئيس الفريق الطبي الناطق بالعربية سابقا ومسؤول عن معالجة البيانات ودقة المحتوى الطبي حاليا.
Türkan Tünerir
أخصائي اعادة تأهيل فيزيائي
39سنة خبره ١٦ سنة
4.7
20 تقييمات
تركيا, Eskisehir
Fizyomer Terapia Physical Therapy and Rehabilitation & Aesthetic & Dental Medical Center

Türkan Tünerir

أخصائي اعادة تأهيل فيزيائي
39سنة خبره ١٦ سنة
  • خبير في العلاج الطبيعي للحالات العضلية الهيكلية والعصبية.
  • أسس مركز إعادة التأهيل الشهير Fizyomer Terapia.
  • يبرع في أساليب مثل العلاج اليدوي، وممارسة الرياضة، والعلاج الكهربائي.
  • الممارسات على المستوى الدولي، ولا سيما في أوروبا والشرق الأوسط.
  • حاصل على شهادات في العلاج الطبيعي وإعادة التأهيل.
  • عضو في المنظمات العالمية للعلاج الطبيعي وإعادة التأهيل.
  • يقدم استشارات عبر الإنترنت لرعاية المرضى عن بعد.
اقرأ المزيد
  • خبير في العلاج الطبيعي للحالات العضلية الهيكلية والعصبية.
  • أسس مركز إعادة التأهيل الشهير Fizyomer Terapia.
  • يبرع في أساليب مثل العلاج اليدوي، وممارسة الرياضة، والعلاج الكهربائي.
  • الممارسات على المستوى الدولي، ولا سيما في أوروبا والشرق الأوسط.
  • حاصل على شهادات في العلاج الطبيعي وإعادة التأهيل.
  • عضو في المنظمات العالمية للعلاج الطبيعي وإعادة التأهيل.
  • يقدم استشارات عبر الإنترنت لرعاية المرضى عن بعد.
اقرأ المزيد
Özgür Ağlamış
طبيب النساء والتوليد
19سنة خبره ١٦ سنة
5.0
2 تقييم
تركيا, إسطنبول
Dr. Özgür Ağlamış's Private Practice

Özgür Ağlamış

طبيب النساء والتوليد
19سنة خبره ١٦ سنة

الدكتورة أوزغور أغلاميس هي طبيبة نسائية وتجميل حاصلة على شهادة البورد الأمريكي ومتخصصة في تجديد شباب المهبل وعلاجات التشنج المهبلي ، وقد تخرجت من جامعة غازي في أنقرة وأكملت تخصصًا في مستشفى زكاي طاهر بوراك للتدريب الصحي للمرأة والبحوث. يتمتع الدكتور أغلاميش بالخبرة في كل من البروتوكولات الجراحية وغير الجراحية ويتحدث الإنجليزية بطلاقة.

اقرأ المزيد

الدكتورة أوزغور أغلاميس هي طبيبة نسائية وتجميل حاصلة على شهادة البورد الأمريكي ومتخصصة في تجديد شباب المهبل وعلاجات التشنج المهبلي ، وقد تخرجت من جامعة غازي في أنقرة وأكملت تخصصًا في مستشفى زكاي طاهر بوراك للتدريب الصحي للمرأة والبحوث. يتمتع الدكتور أغلاميش بالخبرة في كل من البروتوكولات الجراحية وغير الجراحية ويتحدث الإنجليزية بطلاقة.

اقرأ المزيد
Fatih Temiztürk
أخصائي اعادة تأهيل فيزيائي
18سنة خبره ١٦ سنة
4.7
6 تقييمات
تركيا, باموق قلعة
Nobel Medical, Physical Therapy & Rehabilitation Center

Fatih Temiztürk

أخصائي اعادة تأهيل فيزيائي
18سنة خبره ١٦ سنة
الدكتور فاتح تميزتورك متخصص في إعادة التأهيل حاصل على شهادة طبية في عام 2006 من جامعة هاسيتيب. لديه أكثر من 10 سنوات من الخبرة في إعادة التأهيل العصبي والعظام وأمراض الجهاز العضلي الهيكلي وأمراض الروماتيزم ويقوم بإجراء البوتوكس وجميع أنواع علاجات الحقن.اقرأ المزيد
الدكتور فاتح تميزتورك متخصص في إعادة التأهيل حاصل على شهادة طبية في عام 2006 من جامعة هاسيتيب. لديه أكثر من 10 سنوات من الخبرة في إعادة التأهيل العصبي والعظام وأمراض الجهاز العضلي الهيكلي وأمراض الروماتيزم ويقوم بإجراء البوتوكس وجميع أنواع علاجات الحقن.
اقرأ المزيد
Şule Temiztürk
أخصائي اعادة تأهيل فيزيائي
18سنة خبره ١٦ سنة
4.7
6 تقييمات
تركيا, باموق قلعة
Nobel Medical, Physical Therapy & Rehabilitation Center

Şule Temiztürk

أخصائي اعادة تأهيل فيزيائي
18سنة خبره ١٦ سنة
الدكتور شولي تيميزتورك هو أخصائي إعادة تأهيل يتمتع بخبرة تزيد عن 15 عامًا ، وهو متخصص في إعادة التأهيل العصبي والعظام ، واضطرابات الجهاز العضلي الهيكلي ، وأمراض الروماتيزم ، وحقن نقطة الزناد. تخرجت من كلية الطب بجامعة أنقرة عام 2005.اقرأ المزيد
الدكتور شولي تيميزتورك هو أخصائي إعادة تأهيل يتمتع بخبرة تزيد عن 15 عامًا ، وهو متخصص في إعادة التأهيل العصبي والعظام ، واضطرابات الجهاز العضلي الهيكلي ، وأمراض الروماتيزم ، وحقن نقطة الزناد. تخرجت من كلية الطب بجامعة أنقرة عام 2005.
اقرأ المزيد
Abdullah Sakin
أخصائي الأورام / أخصائي الثدي
17سنة خبره ١٦ سنة
5.0
2 تقييم
تركيا, إسطنبول
Medipol Bahçelievler Hospital

Abdullah Sakin

أخصائي الأورام / أخصائي الثدي
17سنة خبره ١٦ سنة

 

Experience

2022 PRIVATE MEDIPOL BAHÇELİEVLER HOSPITAL

 

2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital, Medical Oncology Clinic Education Officer

 

2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital

 

2020 - 2021 Yüzüncü Yıl University Faculty of Medicine

 

2020 - 2021 Head of the Department of Medical Oncology, Yüzüncü Yıl University Faculty of Medicine, Assoc. Dr.  

 

2018 - 2021 Lecturer - Yüzüncü Yıl University Faculty of Medicine, Head of Medical Oncology Department  

 

2018 - 2021 Yüzüncü Yıl University Faculty of Medicine

 

2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital

 

2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Sub-branch assistant

 

2012 - 2015 Kanuni Sultan Süleyman Training and Research Hospital, Internal Medicine specialist

 

2012 - 2015 Suleiman the Magnificent Training and Research Hospital,

 

2008 - 2012 Haseki Training and Research Hospital

 

2006 - 2008 Kızıltepe No. 3 Health Center General Practitioner.

 

 

Education

2018

İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

2018

İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji, İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

2012

İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları, İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

2012

İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

2007

Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi, Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi

 

اقرأ المزيد

 

Experience

2022 PRIVATE MEDIPOL BAHÇELİEVLER HOSPITAL

 

2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital, Medical Oncology Clinic Education Officer

 

2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital

 

2020 - 2021 Yüzüncü Yıl University Faculty of Medicine

 

2020 - 2021 Head of the Department of Medical Oncology, Yüzüncü Yıl University Faculty of Medicine, Assoc. Dr.  

 

2018 - 2021 Lecturer - Yüzüncü Yıl University Faculty of Medicine, Head of Medical Oncology Department  

 

2018 - 2021 Yüzüncü Yıl University Faculty of Medicine

 

2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital

 

2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Sub-branch assistant

 

2012 - 2015 Kanuni Sultan Süleyman Training and Research Hospital, Internal Medicine specialist

 

2012 - 2015 Suleiman the Magnificent Training and Research Hospital,

 

2008 - 2012 Haseki Training and Research Hospital

 

2006 - 2008 Kızıltepe No. 3 Health Center General Practitioner.

 

 

Education

2018

İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

2018

İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji, İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

2012

İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları, İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

2012

İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

2007

Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi, Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi

 

اقرأ المزيد
5.0
2 تقييم
تكلفة استشارة الطبيب السعر عند الطلب
المعالجة بالدم السري $7000 - $9000
المزيد من الطرق العلاجية
Evrim Metcalfe
أخصائي الأورام الإشعاعية
26سنة خبره ١٦ سنة
5.0
2 تقييم
تركيا, إسطنبول
Medipol Bahçelievler Hospital

Evrim Metcalfe

أخصائي الأورام الإشعاعية
26سنة خبره ١٦ سنة

Experience

2021 - 2022

Clinical Manager of Radiation Oncology, Medicana International Istanbul Hospital

2021 - 2022

Department of Radiation Oncology, Biruni University Faculty of Medicine

2020 - 2021

Clinical Manager of Radiation Oncology, Medicana International Istanbul Hospital

2017 - 2020

Clinical Manager of Radiation Oncology, Neolife Medical Center

2016 - 2017

Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine

2011 - 2016

Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine

2010 - 2011

Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine

2008 - 2010

Radiation Oncology Clinic, Samsun Training and Research Hospital (Education Coordinator)

2006

Medical Faculty, Dokuz Eylül University

2006 - 2008

Radiation Oncology Clinic, Samsun Mehmet Aydın State Hospital (Compulsory Service)

2000 - 2006

Medical Faculty, Dokuz Eylül University

 

Education

2022

Biruni University Faculty of Medicine, Department of Radiation Oncology, Faculty Member, Professor Doctor

2022

Anadolu University Open Education Faculty Undergraduate Program, Cultural Heritage and Tourism

2021

Feyziye Schools Foundation Işık University Health Services Vocational School, Faculty Member, Associate Professor Doctor

2017

Eskişehir Osmangazi University Faculty of Medicine, Department of Radiation Oncology, Faculty Member

2017

Eskişehir Osmangazi University Faculty of Medicine, Department of Radiation Oncology, Associate Professor Doctor

2006

Samsun Training and Research Hospital, Specialist Doctor, Compulsory Service

2006

Dokuz Eylül University Faculty of Medicine, Department of Radiation Oncology, Medical Specialization

1998

Ege University, Faculty of Medicine

 

 

اقرأ المزيد

Experience

2021 - 2022

Clinical Manager of Radiation Oncology, Medicana International Istanbul Hospital

2021 - 2022

Department of Radiation Oncology, Biruni University Faculty of Medicine

2020 - 2021

Clinical Manager of Radiation Oncology, Medicana International Istanbul Hospital

2017 - 2020

Clinical Manager of Radiation Oncology, Neolife Medical Center

2016 - 2017

Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine

2011 - 2016

Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine

2010 - 2011

Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine

2008 - 2010

Radiation Oncology Clinic, Samsun Training and Research Hospital (Education Coordinator)

2006

Medical Faculty, Dokuz Eylül University

2006 - 2008

Radiation Oncology Clinic, Samsun Mehmet Aydın State Hospital (Compulsory Service)

2000 - 2006

Medical Faculty, Dokuz Eylül University

 

Education

2022

Biruni University Faculty of Medicine, Department of Radiation Oncology, Faculty Member, Professor Doctor

2022

Anadolu University Open Education Faculty Undergraduate Program, Cultural Heritage and Tourism

2021

Feyziye Schools Foundation Işık University Health Services Vocational School, Faculty Member, Associate Professor Doctor

2017

Eskişehir Osmangazi University Faculty of Medicine, Department of Radiation Oncology, Faculty Member

2017

Eskişehir Osmangazi University Faculty of Medicine, Department of Radiation Oncology, Associate Professor Doctor

2006

Samsun Training and Research Hospital, Specialist Doctor, Compulsory Service

2006

Dokuz Eylül University Faculty of Medicine, Department of Radiation Oncology, Medical Specialization

1998

Ege University, Faculty of Medicine

 

 

اقرأ المزيد
5.0
2 تقييم
تكلفة استشارة الطبيب السعر عند الطلب
المعالجة بالدم السري $7000 - $9000
المزيد من الطرق العلاجية
Erkut Attar
طبيب النساء والتوليد
32سنة خبره ١٦ سنة
4.0
1 تقييم
تركيا, إسطنبول
Yeditepe University Hospital

Erkut Attar

طبيب النساء والتوليد
32سنة خبره ١٦ سنة
الدكتور إركوت عطار هو أخصائي مشهور في أمراض النساء والتوليد، مع التركيز على أمراض الغدد الصماء التناسلية والعقم والمناعة التناسلية. يتمتع بخلفية أكاديمية واسعة حيث حصل على درجات علمية من جامعة إسطنبول وجامعة ييل وجامعة نورث ويسترن. وقد شغل مناصب هامة في كل من المجالين السريري والأكاديمي، وحاز على العديد من الجوائز مثل جائزة الجمعية الأمريكية للطب التناسلي للمناعة التناسلية وجائزة الجمعية الأمريكية لطب المناعة التناسلية للسفر. وهو أيضاً المؤسس والرئيس الحالي لجمعية آلام الحوض وبطانة الرحم في تركيا.اقرأ المزيد
الدكتور إركوت عطار هو أخصائي مشهور في أمراض النساء والتوليد، مع التركيز على أمراض الغدد الصماء التناسلية والعقم والمناعة التناسلية. يتمتع بخلفية أكاديمية واسعة حيث حصل على درجات علمية من جامعة إسطنبول وجامعة ييل وجامعة نورث ويسترن. وقد شغل مناصب هامة في كل من المجالين السريري والأكاديمي، وحاز على العديد من الجوائز مثل جائزة الجمعية الأمريكية للطب التناسلي للمناعة التناسلية وجائزة الجمعية الأمريكية لطب المناعة التناسلية للسفر. وهو أيضاً المؤسس والرئيس الحالي لجمعية آلام الحوض وبطانة الرحم في تركيا.
اقرأ المزيد
Akif Nuri Dogan
طبيب عام
22سنة خبره ١٦ سنة
4.5
138 تقييمات
تركيا, إسطنبول
Hisar Intercontinental Hospital

Akif Nuri Dogan

طبيب عام
22سنة خبره ١٦ سنة
الدكتور عاكف نوري دوغان هو طبيب تخرج من كلية الطب Cerrahpaşa ، جامعة اسطنبول في عام 2002 وأكمل تدريب الإقامة في عام 2008 في وزارة الصحة ، مستشفى Bezm-i Alem Vakıf Gureba للتعليم والبحوث. يقدم خدمات التقييم والتشخيص التفريقي والعلاج والمراقبة للمرضى الذين يعانون من أمراض داخلية في مستشفى حصار انتركونتيننتال ومتخصص في السمنة والارتجاع وارتفاع ضغط الدم والسكري والتعب المزمن. كما تدرب وعمل في مستشفى إيلازيج العسكري في أنطاليا للتدريب والبحوث ، ومستشفى أكسيكي الحكومي بوزارة الصحة ، ومستشفى بيزم-إليم فاكيف جوريبا للتدريب والبحوث.اقرأ المزيد
الدكتور عاكف نوري دوغان هو طبيب تخرج من كلية الطب Cerrahpaşa ، جامعة اسطنبول في عام 2002 وأكمل تدريب الإقامة في عام 2008 في وزارة الصحة ، مستشفى Bezm-i Alem Vakıf Gureba للتعليم والبحوث. يقدم خدمات التقييم والتشخيص التفريقي والعلاج والمراقبة للمرضى الذين يعانون من أمراض داخلية في مستشفى حصار انتركونتيننتال ومتخصص في السمنة والارتجاع وارتفاع ضغط الدم والسكري والتعب المزمن. كما تدرب وعمل في مستشفى إيلازيج العسكري في أنطاليا للتدريب والبحوث ، ومستشفى أكسيكي الحكومي بوزارة الصحة ، ومستشفى بيزم-إليم فاكيف جوريبا للتدريب والبحوث.
اقرأ المزيد
Ibrahim Ural
أخصائي إعادة تأهيل الأطفال
24سنة خبره ١٦ سنة
4.7
36 تقييمات
تركيا, إسطنبول
Valued Med Hub Hospitals

Ibrahim Ural

أخصائي إعادة تأهيل الأطفال
24سنة خبره ١٦ سنة

Education and Expertise

1993-1999 Istanbul University Istanbul Faculty of Medicine

2000-2005 Istanbul University, Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation, specialization training

 

Experience

2020 - …: Beykent University Faculty of Medicine Department of Physical Medicine and Rehabilitation

2015 - 2020: Bahçeşehir University Faculty of Medicine Department of Physical Medicine and Rehabilitation

2008 -2021: Medical Park Fatih Hospital Physical Medicine and Rehabilitation Clinic

2007 - 2008: Elazig Military Hospital Physical Therapy Clinic

2005 - 2007: Bayrampaşa Physical Therapy and Rehabilitation Center for the Disabled

2000 - 2005: Istanbul University, Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation

 

Professional Memberships

1. Turkish Medical Association

2. Turkish Physical Medicine and Rehabilitation Association

3. Member of Istanbul Medical Chamber,

4.Pediatric Rehabilitation Association

 

Awards

1 - National Thoracic Oncology Congress, p38, Antalya, 2008 (BEST POSTER AWARD). Demir A, M. Z. Gunluoğlu, N. Dağoğlu, A.Turna, Y. Dizdar, K. Kaynak, Ş. Dilege, N.M. Molinas, D. Yilmazbayhan, S.İ.Dinçer, A.Gürses “The role and prognosis of surgery in the treatment of chest wall primitive neuroectodermal tumors”.

2 - National Thoracic Oncology Congress, 109, Marmaris, 2007 (BEST ORAL PRESENTATION AWARD) Melek, H., M. Günlüoğlu, A. Demir, B. Medetoğlu, H.V. Kara, A. Ölçmen, S.İ. Dinçer, "The superiority of Computed Tomography-integrated PET (PET-CT) over PET fusion CT in Mediastinal Staging of Lung Cancer".

3 - Thoracic Society 9th Annual Congress, 92, Antalya, 2006. (BEST DISCUSSIVE POSTER AWARD) Fazlıoğlu, M., C. Kocatürk, Y. Sönmezoğlu, A.G. Cevik, A. Demir, N. Ürer, A.Turna, S.İ. Dincer M.A. Bedirhan and A. Gürses, “The effect of NSCLC with chest wall invasion DA depth of invasion and resection type on survival”.

4 - National Thoracic Oncology Congress, TP , Çeşme, 2006. (BEST DISCUSSIVE POSTER AWARD).Günlüoğlu, M.Z., A. Demir, H. Akın, D. Sansar, H.V. Kara, A. Ölçmen and S.İ. Dinçer, “Mediastinal lymphatic metastasis pattern in left upper lobe non-small cell lung cancer”. Education and Specialization

1993-1999 Istanbul University Istanbul Faculty of Medicine

2000-2005 Istanbul University, Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation, specialization training

 

Experience

2020 - …: Beykent University Faculty of Medicine Department of Physical Medicine and Rehabilitation

2015 - 2020: Bahçeşehir University Faculty of Medicine Department of Physical Medicine and Rehabilitation

2008 -2021: Medical Park Fatih Hospital Physical Medicine and Rehabilitation Clinic

2007 - 2008: Elazig Military Hospital Physical Therapy Clinic

2005 - 2007: Bayrampaşa Physical Therapy and Rehabilitation Center for the Disabled

2000 - 2005: Istanbul University, Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation

 

Professional Memberships

1. Turkish Medical Association

2. Turkish Physical Medicine and Rehabilitation Association

3. Member of Istanbul Medical Chamber,

4.Pediatric Rehabilitation Association

 

Awards

1 - National Thoracic Oncology Congress, p38, Antalya, 2008 (BEST POSTER AWARD). Demir A, M. Z. Gunluoğlu, N. Dağoğlu, A.Turna, Y. Dizdar, K. Kaynak, Ş. Dilege, N.M. Molinas, D. Yilmazbayhan, S.İ.Dinçer, A.Gürses “The role and prognosis of surgery in the treatment of chest wall primitive neuroectodermal tumors”.

2 - National Thoracic Oncology Congress, 109, Marmaris, 2007 (BEST ORAL PRESENTATION AWARD) Melek, H., M. Günlüoğlu, A. Demir, B. Medetoğlu, H.V. Kara, A. Ölçmen, S.İ. Dinçer, "The superiority of Computed Tomography-integrated PET (PET-CT) over PET fusion CT in Mediastinal Staging of Lung Cancer".

3 - Thoracic Society 9th Annual Congress, 92, Antalya, 2006. (BEST DISCUSSIVE POSTER AWARD) Fazlıoğlu, M., C. Kocatürk, Y. Sönmezoğlu, A.G. Cevik, A. Demir, N. Ürer, A.Turna, S.İ. Dincer M.A. Bedirhan and A. Gürses, “The effect of NSCLC with chest wall invasion DA depth of invasion and resection type on survival”.

4 - National Thoracic Oncology Congress, TP , Çeşme, 2006. (BEST DISCUSSIVE POSTER AWARD).Günlüoğlu, M.Z., A. Demir, H. Akın, D. Sansar, H.V. Kara, A. Ölçmen and S.İ. Dinçer, “Mediastinal lymphatic metastasis pattern in left upper lobe non-small cell lung cancer”.

اقرأ المزيد

Education and Expertise

1993-1999 Istanbul University Istanbul Faculty of Medicine

2000-2005 Istanbul University, Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation, specialization training

 

Experience

2020 - …: Beykent University Faculty of Medicine Department of Physical Medicine and Rehabilitation

2015 - 2020: Bahçeşehir University Faculty of Medicine Department of Physical Medicine and Rehabilitation

2008 -2021: Medical Park Fatih Hospital Physical Medicine and Rehabilitation Clinic

2007 - 2008: Elazig Military Hospital Physical Therapy Clinic

2005 - 2007: Bayrampaşa Physical Therapy and Rehabilitation Center for the Disabled

2000 - 2005: Istanbul University, Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation

 

Professional Memberships

1. Turkish Medical Association

2. Turkish Physical Medicine and Rehabilitation Association

3. Member of Istanbul Medical Chamber,

4.Pediatric Rehabilitation Association

 

Awards

1 - National Thoracic Oncology Congress, p38, Antalya, 2008 (BEST POSTER AWARD). Demir A, M. Z. Gunluoğlu, N. Dağoğlu, A.Turna, Y. Dizdar, K. Kaynak, Ş. Dilege, N.M. Molinas, D. Yilmazbayhan, S.İ.Dinçer, A.Gürses “The role and prognosis of surgery in the treatment of chest wall primitive neuroectodermal tumors”.

2 - National Thoracic Oncology Congress, 109, Marmaris, 2007 (BEST ORAL PRESENTATION AWARD) Melek, H., M. Günlüoğlu, A. Demir, B. Medetoğlu, H.V. Kara, A. Ölçmen, S.İ. Dinçer, "The superiority of Computed Tomography-integrated PET (PET-CT) over PET fusion CT in Mediastinal Staging of Lung Cancer".

3 - Thoracic Society 9th Annual Congress, 92, Antalya, 2006. (BEST DISCUSSIVE POSTER AWARD) Fazlıoğlu, M., C. Kocatürk, Y. Sönmezoğlu, A.G. Cevik, A. Demir, N. Ürer, A.Turna, S.İ. Dincer M.A. Bedirhan and A. Gürses, “The effect of NSCLC with chest wall invasion DA depth of invasion and resection type on survival”.

4 - National Thoracic Oncology Congress, TP , Çeşme, 2006. (BEST DISCUSSIVE POSTER AWARD).Günlüoğlu, M.Z., A. Demir, H. Akın, D. Sansar, H.V. Kara, A. Ölçmen and S.İ. Dinçer, “Mediastinal lymphatic metastasis pattern in left upper lobe non-small cell lung cancer”. Education and Specialization

1993-1999 Istanbul University Istanbul Faculty of Medicine

2000-2005 Istanbul University, Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation, specialization training

 

Experience

2020 - …: Beykent University Faculty of Medicine Department of Physical Medicine and Rehabilitation

2015 - 2020: Bahçeşehir University Faculty of Medicine Department of Physical Medicine and Rehabilitation

2008 -2021: Medical Park Fatih Hospital Physical Medicine and Rehabilitation Clinic

2007 - 2008: Elazig Military Hospital Physical Therapy Clinic

2005 - 2007: Bayrampaşa Physical Therapy and Rehabilitation Center for the Disabled

2000 - 2005: Istanbul University, Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation

 

Professional Memberships

1. Turkish Medical Association

2. Turkish Physical Medicine and Rehabilitation Association

3. Member of Istanbul Medical Chamber,

4.Pediatric Rehabilitation Association

 

Awards

1 - National Thoracic Oncology Congress, p38, Antalya, 2008 (BEST POSTER AWARD). Demir A, M. Z. Gunluoğlu, N. Dağoğlu, A.Turna, Y. Dizdar, K. Kaynak, Ş. Dilege, N.M. Molinas, D. Yilmazbayhan, S.İ.Dinçer, A.Gürses “The role and prognosis of surgery in the treatment of chest wall primitive neuroectodermal tumors”.

2 - National Thoracic Oncology Congress, 109, Marmaris, 2007 (BEST ORAL PRESENTATION AWARD) Melek, H., M. Günlüoğlu, A. Demir, B. Medetoğlu, H.V. Kara, A. Ölçmen, S.İ. Dinçer, "The superiority of Computed Tomography-integrated PET (PET-CT) over PET fusion CT in Mediastinal Staging of Lung Cancer".

3 - Thoracic Society 9th Annual Congress, 92, Antalya, 2006. (BEST DISCUSSIVE POSTER AWARD) Fazlıoğlu, M., C. Kocatürk, Y. Sönmezoğlu, A.G. Cevik, A. Demir, N. Ürer, A.Turna, S.İ. Dincer M.A. Bedirhan and A. Gürses, “The effect of NSCLC with chest wall invasion DA depth of invasion and resection type on survival”.

4 - National Thoracic Oncology Congress, TP , Çeşme, 2006. (BEST DISCUSSIVE POSTER AWARD).Günlüoğlu, M.Z., A. Demir, H. Akın, D. Sansar, H.V. Kara, A. Ölçmen and S.İ. Dinçer, “Mediastinal lymphatic metastasis pattern in left upper lobe non-small cell lung cancer”.

اقرأ المزيد
Omer Uslukaya
جراح عام
22سنة خبره ١٦ سنة
4.4
45 تقييمات
تركيا, إسطنبول
Memorial Ataşehir Hospital

Omer Uslukaya

جراح عام
22سنة خبره ١٦ سنة

EXPERIENCE*

 

2019 - Present, Istanbul/Istanbul/Turkey

MEMORIAL ATAŞEHİR HOSPITAL

General Surgeon

2012 - 2019, Diyarbakır/Diyarbakır/Turkey

DİCLE UNIVERSITY FACULTY OF MEDICINE

General Surgeon

2011 - 2012, Van/Van/Turkey

VAN REGIONAL TRAINING AND RESEARCH HOSPITAL

General Surgeon

2009 - 2011, Van/Van/Turkey

HAKKARİ STATE HOSPITAL

General Surgeon

2004 - 2009, Van/Van/Turkey

YÜZÜNCÜYIL UNIVERSITY FACULTY OF MEDICINE

General Surgeon

2002 - 2004, Van/Van/Turkey

HACIBEKİR HEALTH CENTER

General Practitioner

 

*EDUCATION*

 

2018 - 2019, Diyarbakır/Turkey

Associate Professor

2015, Ohio/USA

OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

Neck Dissection Training

2012 - 2018, Diyarbakır/Turkey

Assistant Professor

1996 - 2002, Adana/Turkey

ÇUKUROVA UNIVERSITY

FACULTY OF MEDICINE - Medical Doctor Education

اقرأ المزيد

EXPERIENCE*

 

2019 - Present, Istanbul/Istanbul/Turkey

MEMORIAL ATAŞEHİR HOSPITAL

General Surgeon

2012 - 2019, Diyarbakır/Diyarbakır/Turkey

DİCLE UNIVERSITY FACULTY OF MEDICINE

General Surgeon

2011 - 2012, Van/Van/Turkey

VAN REGIONAL TRAINING AND RESEARCH HOSPITAL

General Surgeon

2009 - 2011, Van/Van/Turkey

HAKKARİ STATE HOSPITAL

General Surgeon

2004 - 2009, Van/Van/Turkey

YÜZÜNCÜYIL UNIVERSITY FACULTY OF MEDICINE

General Surgeon

2002 - 2004, Van/Van/Turkey

HACIBEKİR HEALTH CENTER

General Practitioner

 

*EDUCATION*

 

2018 - 2019, Diyarbakır/Turkey

Associate Professor

2015, Ohio/USA

OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

Neck Dissection Training

2012 - 2018, Diyarbakır/Turkey

Assistant Professor

1996 - 2002, Adana/Turkey

ÇUKUROVA UNIVERSITY

FACULTY OF MEDICINE - Medical Doctor Education

اقرأ المزيد
Leyla Celebi
طبيب نفساني للاطفال
5سنة خبره ١٦ سنة

Leyla Celebi

طبيب نفساني للاطفال
5سنة خبره ١٦ سنة
تركيا, إسطنبول
Moodist Psychiatry and Neurology Hospital
Suveybe Tekin
طبيب نفسي
3سنة خبره ١٦ سنة

Suveybe Tekin

طبيب نفسي
3سنة خبره ١٦ سنة
تركيا, إسطنبول
Moodist Psychiatry and Neurology Hospital
Aisha
اخصائي زراعة الشعر
13سنة خبره ١٦ سنة

Aisha

اخصائي زراعة الشعر
13سنة خبره ١٦ سنة
تركيا, أنطاليا
Medpearl Group
Didem Altay Gazi
طبيب عام
34سنة خبره ١٦ سنة
5.0
4 تقييمات
تركيا, إسطنبول
Liv Hospital Vadistanbul

Didem Altay Gazi

طبيب عام
34سنة خبره ١٦ سنة

Education: 

İstanbul Pertevniyal Anatolian High School 

Trakya University Faculty of Medicine 

İstanbul Okmeydanı Training And Research Hospital Family Practice 

Experience: 

Liv Hospital Ulus 2021-  

Acıbadem Fulya Hospital 

Adıyaman Sincik District State Hospital 

Okmeydanı Training and Research Hospital 

İstanbul Gaziosmanpaşa Karlıtepe A.H.D, Bağlarbaşı A.H.D. and Pazariçi A.H.D

Memberships: 

Turkish Medical Association (Istanbul Chamber of Doctors) 

TAHUD (Turkish Family Physicians Specialty Association)

اقرأ المزيد

Education: 

İstanbul Pertevniyal Anatolian High School 

Trakya University Faculty of Medicine 

İstanbul Okmeydanı Training And Research Hospital Family Practice 

Experience: 

Liv Hospital Ulus 2021-  

Acıbadem Fulya Hospital 

Adıyaman Sincik District State Hospital 

Okmeydanı Training and Research Hospital 

İstanbul Gaziosmanpaşa Karlıtepe A.H.D, Bağlarbaşı A.H.D. and Pazariçi A.H.D

Memberships: 

Turkish Medical Association (Istanbul Chamber of Doctors) 

TAHUD (Turkish Family Physicians Specialty Association)

اقرأ المزيد
Sebnem Sanem Akcayoz
أخصائي اعادة تأهيل فيزيائي
16سنة خبره ١٦ سنة

Sebnem Sanem Akcayoz

أخصائي اعادة تأهيل فيزيائي
16سنة خبره ١٦ سنة
تركيا, إسطنبول
Moodist Psychiatry and Neurology Hospital
Kadir Idin
طبيب تخدير
27سنة خبره ١٦ سنة
5.0
2 تقييم
تركيا, إسطنبول
Medipol Bahçelievler Hospital

Kadir Idin

طبيب تخدير
27سنة خبره ١٦ سنة

Experience

2016 - 2022

ISTANBUL MEDIPOL UNIVERSITY

2010 - 2016

BEZM-I ÂLEM FOUNDATION UNIVERSITY

2010 - 2015

Bezmialem Vakif University Faculty of Medicine

2009 - 2010

Bagcilar Training and Research Hospital

2009 - 2010

ISTANBUL BAGCILAR TRAINING AND RESEARCH HOSPITAL

1997 - 2009

ISTANBUL HASEKI TRAINING AND RESEARCH HOSPITAL

1997 - 2009

Haseki Training and Research Hospital

 

Education

2016

BEZM-I ÂLEM FOUNDATION UNIVERSITY, DEPARTMENT OF ANESTHESIOLOGY AND REANIMATION

1997

Istanbul Haseki Training and Research Hospital, Anesthesiology and Reanimation

1993

ISTANBUL HASEKI TRAINING AND RESEARCH HOSPITAL, Medical Specialization

1989

Istanbul University, Faculty of Medicine

1983

ISTANBUL UNIVERSITY, CERRAHPAŞA FACULTY OF MEDICINE, FACULTY OF MEDICINE

اقرأ المزيد

Experience

2016 - 2022

ISTANBUL MEDIPOL UNIVERSITY

2010 - 2016

BEZM-I ÂLEM FOUNDATION UNIVERSITY

2010 - 2015

Bezmialem Vakif University Faculty of Medicine

2009 - 2010

Bagcilar Training and Research Hospital

2009 - 2010

ISTANBUL BAGCILAR TRAINING AND RESEARCH HOSPITAL

1997 - 2009

ISTANBUL HASEKI TRAINING AND RESEARCH HOSPITAL

1997 - 2009

Haseki Training and Research Hospital

 

Education

2016

BEZM-I ÂLEM FOUNDATION UNIVERSITY, DEPARTMENT OF ANESTHESIOLOGY AND REANIMATION

1997

Istanbul Haseki Training and Research Hospital, Anesthesiology and Reanimation

1993

ISTANBUL HASEKI TRAINING AND RESEARCH HOSPITAL, Medical Specialization

1989

Istanbul University, Faculty of Medicine

1983

ISTANBUL UNIVERSITY, CERRAHPAŞA FACULTY OF MEDICINE, FACULTY OF MEDICINE

اقرأ المزيد
5.0
2 تقييم
تكلفة استشارة الطبيب السعر عند الطلب
المعالجة بالدم السري $7000 - $9000
المزيد من الطرق العلاجية
Omer Alyan
طبيب قلب
26سنة خبره ١٦ سنة
5.0
2 تقييم
تركيا, إسطنبول
Medipol Bahçelievler Hospital

Omer Alyan

طبيب قلب
26سنة خبره ١٦ سنة

Experience

2018 - 2022

Health Sciences University – Şişli Hamidiye Etfal Training and Research Hospital

2016 - 2018

Diyarbakır Memorial Dicle Hospital Cardiology Clinic

2010 - 2010

Dicle University Faculty of Medicine, Department of Cardiology

2010 - 2016

Private Veni Vidi Hospital, Cardiology Clinic Supervisor

2006 - 2010

Dicle University Faculty of Medicine, Department of Cardiology

2005 - 2006

Urfa State Hospital

1999 - 2005

Turkey High Specialization Training and Research Hospital

1998 - 1999

Duruca Health Center

 

Education

2018

Health Sciences University, Cardiology

2010

Dicle University, Department of Cardiology

2005

Cardiology Turkey High Specialization Training and Research Hospital, Medical Specialization

1998

Ege University, Faculty of Medicine

اقرأ المزيد

Experience

2018 - 2022

Health Sciences University – Şişli Hamidiye Etfal Training and Research Hospital

2016 - 2018

Diyarbakır Memorial Dicle Hospital Cardiology Clinic

2010 - 2010

Dicle University Faculty of Medicine, Department of Cardiology

2010 - 2016

Private Veni Vidi Hospital, Cardiology Clinic Supervisor

2006 - 2010

Dicle University Faculty of Medicine, Department of Cardiology

2005 - 2006

Urfa State Hospital

1999 - 2005

Turkey High Specialization Training and Research Hospital

1998 - 1999

Duruca Health Center

 

Education

2018

Health Sciences University, Cardiology

2010

Dicle University, Department of Cardiology

2005

Cardiology Turkey High Specialization Training and Research Hospital, Medical Specialization

1998

Ege University, Faculty of Medicine

اقرأ المزيد
5.0
2 تقييم
تكلفة استشارة الطبيب السعر عند الطلب
المعالجة بالدم السري $7000 - $9000
المزيد من الطرق العلاجية
Dursun Aras
طبيب قلب
28سنة خبره ١٦ سنة
5.0
2 تقييم
تركيا, إسطنبول
Medipol Bahçelievler Hospital

Dursun Aras

طبيب قلب
28سنة خبره ١٦ سنة

Experience

2019 - 2022

University of Health Sciences, Faculty of Medicine, Ankara City Hospital, Cardiology Clinic, Ankara

2017 - 2019

University of Health Sciences, Faculty of Medicine, Turkey Higher Specialization Training and Research Hospital, Cardiology Clinic, Ankara,

2012 - 2017

Türkiye Higher Specialization Training and Research Hospital, Cardiology Clinic, Ankara,

2012 - 2017

T.R. Karabük University, Faculty of Medicine, Department of Cardiology

2006 - 2006

Türkiye Higher Specialization Training and Research Hospital, Cardiology Clinic, Ankara,

2001 - 2006

Türkiye Higher Specialization Training and Research Hospital, Cardiology Clinic, Ankara,

1996 - 2001

Türkiye Higher Specialization Training and Research Hospital, Cardiology Clinic, Ankara,

 

Education

2017 Karabük University, Faculty of Medicine, Department of Cardiology

 

2006 Türkiye Higher Specialization Training and Research Hospital, Cardiology Clinic

 

2001 Türkiye Higher Specialization Training and Research Hospital, Ankara, Cardiology

 

1996 Ankara University, Faculty of Medicine

اقرأ المزيد

Experience

2019 - 2022

University of Health Sciences, Faculty of Medicine, Ankara City Hospital, Cardiology Clinic, Ankara

2017 - 2019

University of Health Sciences, Faculty of Medicine, Turkey Higher Specialization Training and Research Hospital, Cardiology Clinic, Ankara,

2012 - 2017

Türkiye Higher Specialization Training and Research Hospital, Cardiology Clinic, Ankara,

2012 - 2017

T.R. Karabük University, Faculty of Medicine, Department of Cardiology

2006 - 2006

Türkiye Higher Specialization Training and Research Hospital, Cardiology Clinic, Ankara,

2001 - 2006

Türkiye Higher Specialization Training and Research Hospital, Cardiology Clinic, Ankara,

1996 - 2001

Türkiye Higher Specialization Training and Research Hospital, Cardiology Clinic, Ankara,

 

Education

2017 Karabük University, Faculty of Medicine, Department of Cardiology

 

2006 Türkiye Higher Specialization Training and Research Hospital, Cardiology Clinic

 

2001 Türkiye Higher Specialization Training and Research Hospital, Ankara, Cardiology

 

1996 Ankara University, Faculty of Medicine

اقرأ المزيد
5.0
2 تقييم
تكلفة استشارة الطبيب السعر عند الطلب
المعالجة بالدم السري $7000 - $9000
المزيد من الطرق العلاجية
Nail Paksoy
أخصائي الأورام / أخصائي الثدي
13سنة خبره ١٦ سنة
5.0
2 تقييم
تركيا, إسطنبول
Medipol Bahçelievler Hospital

Nail Paksoy

أخصائي الأورام / أخصائي الثدي
13سنة خبره ١٦ سنة


PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

 

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

 

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

  • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
  • Role: Subinvestigator

2. PFİZER

  • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
  • Role: Subinvestigator

3. RECITE - AMGEN

  • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
  • Role: Subinvestigator

4. NAVIGATE - BAYER

  • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
  • Role: Subinvestigator

5. RUBY - Tesaro (PRA)

  • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
  • Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

  • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
  • Role: Subinvestigator

7. ASTRA ZENECA

  • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
  • Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

  • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
  • Role: Subinvestigator
  •  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

  • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
  • Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

  • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
  • Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

  • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
  • Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

  • Authors: Paksoy, Nail, et al.
  • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

  • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
  • Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

  • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
  • Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

  • Authors: HAS SIMSEK, Duygu, et al.
  • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

  • Authors: TURAL, Deniz, et al.
  • Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

  • Authors: FERHATOGLU, Ferhat, et al.
  • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

  • Authors: TURAL, Deniz, et al.
  • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

  • Authors: GÜRBÜZ, Mustafa, et al.
  • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

  • Authors: AY, Seval, et al.
  • Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

  • Authors: CIL, Ibrahim, et al.
  • Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

  • Authors: HIZAL, Mutlu, et al.
  • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

  • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
  • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

  • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
  • Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

  • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

  • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
  • Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

  • Authors: DEMIR, Semra, et al.
  • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

  • Authors: ÖZDEMIR, Seçil Kepil, et al.
  • Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

  • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
  • Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

  • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
  • Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

  • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
  • Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

  • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
  • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

  • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
  • Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

  • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
  • Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

  • Authors: Dogan, I., Paksoy, N., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

  • Authors: Dogan, I., Paksoy, N., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

  • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

  • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
  • Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

  • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
  • Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

  • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
  • Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

  • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
  • Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

 

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

  • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

  • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

  • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

  • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

  • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

  • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

  • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

  • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

  • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

  • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

 

 

اقرأ المزيد


PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

 

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

 

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

  • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
  • Role: Subinvestigator

2. PFİZER

  • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
  • Role: Subinvestigator

3. RECITE - AMGEN

  • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
  • Role: Subinvestigator

4. NAVIGATE - BAYER

  • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
  • Role: Subinvestigator

5. RUBY - Tesaro (PRA)

  • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
  • Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

  • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
  • Role: Subinvestigator

7. ASTRA ZENECA

  • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
  • Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

  • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
  • Role: Subinvestigator
  •  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

  • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
  • Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

  • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
  • Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

  • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
  • Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

  • Authors: Paksoy, Nail, et al.
  • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

  • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
  • Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

  • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
  • Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

  • Authors: HAS SIMSEK, Duygu, et al.
  • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

  • Authors: TURAL, Deniz, et al.
  • Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

  • Authors: FERHATOGLU, Ferhat, et al.
  • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

  • Authors: TURAL, Deniz, et al.
  • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

  • Authors: GÜRBÜZ, Mustafa, et al.
  • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

  • Authors: AY, Seval, et al.
  • Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

  • Authors: CIL, Ibrahim, et al.
  • Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

  • Authors: HIZAL, Mutlu, et al.
  • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

  • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
  • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

  • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
  • Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

  • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

  • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
  • Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

  • Authors: DEMIR, Semra, et al.
  • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

  • Authors: ÖZDEMIR, Seçil Kepil, et al.
  • Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

  • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
  • Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

  • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
  • Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

  • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
  • Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

  • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
  • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

  • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
  • Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

  • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
  • Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

  • Authors: Dogan, I., Paksoy, N., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

  • Authors: Dogan, I., Paksoy, N., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

  • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

  • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
  • Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

  • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
  • Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

  • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
  • Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

  • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
  • Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

 

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

  • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

  • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

  • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

  • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

  • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

  • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

  • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

  • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

  • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

  • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

 

 

اقرأ المزيد
5.0
2 تقييم
تكلفة استشارة الطبيب السعر عند الطلب
المعالجة بالدم السري $7000 - $9000
المزيد من الطرق العلاجية
Selin Birgul Baran
طبيب نفسي
27سنة خبره ١٦ سنة

Selin Birgul Baran

طبيب نفسي
27سنة خبره ١٦ سنة
تركيا, إسطنبول
Moodist Psychiatry and Neurology Hospital